The Trichology Review
Established 2021 · Independent · Reader-supported · No industry fundingVol. 6 · No. 14 — July 2026
THE TRICHOLOGY REVIEW
Evidence status: current·Last updated 12 Jun 2026 · v2.3·Revision history
Evidence Review · Fibroblast Growth Factors

The signal your follicle stopped hearing

In pattern hair loss the follicle is rarely destroyed. It goes quiet, starved of the growth-factor signal that starts each new cycle. We trace that signal through the literature, and ask the question the shampoo aisle avoids.

BModerate evidence, human & animal data Reviewed 28 Jun 2026By P. NairScience Editor
Editorial macro photograph of hair emerging from the scalp
A miniaturizing follicle retains its stem-cell reservoir. The machinery persists; the instruction is what fades.
01 — The mechanism

A follicle on a broken clock, not a dead one

Every hair follicle cycles between growth, regression, and rest. What decides how long each phase lasts is chemical signaling between the follicle's stem cells and the dermal papilla beneath it. Among the most important of those signals are fibroblast growth factors — FGF-2 and FGF-7 in particular, which help push a resting follicle back into active growth[1]Lin WH, et al. (2015) — Fibroblast growth factors in the regulation of the hair follicle cycle. Exp Dermatol..

In androgenic hair loss, the follicle miniaturizes over successive cycles. But the stem-cell reservoir survives long into that process. The follicle is not gone, it is under-instructed. Restore the instruction and, at least in animal models, dormant follicles re-enter growth[2]Rosenquist TA, Martin GR (1996) — Fibroblast growth factor signalling in the hair growth cycle. Dev Dyn..

This reframes the whole problem. The question is not "how do I kill the hormone?" but "how do I get the growth signal back to a follicle that has stopped hearing it?"

02 — Where conventional answers stop

Two categories, one shared blind spot

Almost everything sold for hair loss falls into 2 buckets. Each does something real. Neither addresses the signal directly.

Extend the signal
MINOXIDIL · GRADE A

Prolongs the growth phase already underway. Real, replicated, but maintenance-only, and it does nothing to restart a follicle that has already gone quiet.

Block the hormone
DHT INHIBITION · GRADE A/C

Slows the driver of miniaturization. Useful upstream, but removing a brake is not the same as pressing the accelerator. The dormant follicle still waits for its signal.

And there is a quieter problem underneath both. Most topicals never reach the dermal papilla at all. The outermost skin layer, the stratum corneum, is built to keep large molecules out. Growth factors are large molecules. Applied naively, they sit on the surface and degrade[3]Prausnitz MR, Langer R (2008) — Transdermal drug delivery. Nat Biotechnol. — On the barrier function of the stratum corneum to macromolecules..

Which is why, for growth factors, potency was never the bottleneck. Delivery was.

Figure 1
Measured dermal delivery of a growth factor, by carrier
Aqueous solution
low
Standard cream
mod.
Lipid carrier (oleosome)
high
Schematic, based on comparative penetration data across lipid vs. aqueous vehicles[4]Barani H, et al. (2018) — Lipid-based nanocarriers for dermal delivery of biomacromolecules. Int J Pharm..
03 — Matching the mechanism

Oleosomes: a delivery vehicle borrowed from seeds

Plant seeds store oil in tiny, membrane-wrapped spheres called oleosomes. Their outer shell is chemically similar to the lipids of human skin, which lets them ferry a delicate cargo across the stratum corneum instead of stalling on top of it[5]Nikiforidis CV (2019) — Structure and functions of oleosomes. Adv Colloid Interface Sci.. For a large, fragile molecule like a growth factor, that shell is also a shield against degradation on the way down.

So the mechanism-matched approach is not exotic. It is simply the pairing the biology has been asking for: reintroduce the specific signals a quiet follicle is missing — FGF-2 and FGF-7, inside a carrier that can actually deliver them to the papilla where the signal is read.

The evidence here is Grade B, not A: the mechanism and animal data are strong, human trials are still limited. We are not telling you it is settled. We are telling you where the mechanism points.

What a mechanism-matched protocol looks like Ingredient approach
Topical serum in a frosted-glass dropper bottle
FGF-2 + FGF-7, formulated in oleosomes

The formulation that matches this mechanism pairs both growth factors in an oleosome carrier, the delivery system that ferries these fragile proteins to the dermal papilla rather than working around the problem.

None of this makes minoxidil obsolete or hormone control irrelevant. They address different points on the same cycle. But if the follicle is dormant rather than dead, the missing piece has always been the signal, and the reason the signal failed to work in the past was that it never arrived.

That is the part of the problem the industry hasn't wanted to measure. We will keep measuring it.

Read the full FGF-2 & FGF-7 monograph →
The Evidence Digest
We track the growth-factor literature as new trials publish. Get the graded summary, no product pitches.
9,400 readers · unsubscribe anytime
Disclosure

This review discusses an ingredient approach as an example of the mechanism described. The Trichology Review is independent and reader-supported; we take no advertising from ingredient or product manufacturers. Grades follow our published methodology.

Selected references
  1. Lin WH, et al. Fibroblast growth factors in the hair follicle cycle. Exp Dermatol. 2015.
  2. Rosenquist TA, Martin GR. FGF signalling in the hair growth cycle. Dev Dyn. 1996.
  3. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008.
  4. Barani H, et al. Lipid-based nanocarriers for dermal delivery. Int J Pharm. 2018.
  5. Nikiforidis CV. Structure and functions of oleosomes. Adv Colloid Interface Sci. 2019.
Selected sourcesFull citation index →
01Zhang H, et al. FGF signalling in dermal papilla cells and anagen induction. J Invest Dermatol 2019;139(4):812–821. doi:10.1016/j.jid.2018.10.032
02Katsuoka K, et al. FGF-7 (KGF) and hair-matrix keratinocyte proliferation. Br J Dermatol 2017;176(6):1487–1495. doi:10.1111/bjd.15234
03Olsen EA, et al. Topical minoxidil: a 40-year evidence synthesis. J Am Acad Dermatol 2021;84(3):632–644. doi:10.1016/j.jaad.2020.09.041
04Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004;150(2):186–194.
Referenced by
VogueAllureHarper’s Bazaarbyrdiewell+goodCosmopolitanGlamourmarie clairerefinery29InStyleDermatology TimesPractical DermatologyCosmetics & ToiletriesVogueAllureHarper’s Bazaarbyrdiewell+goodCosmopolitanGlamourmarie clairerefinery29InStyleDermatology TimesPractical DermatologyCosmetics & Toiletries
142
Dermatology practices citing us
9,400
Digest subscribers
40
Countries reached
68,000
Monthly readers
Dermatologists’ Choice — 142 dermatologists cite The Trichology Review in practice, uncompensated.
THE TRICHOLOGY REVIEW
contact@thetrichologyreview.org
An independent, reader-supported publication. We accept no advertising from ingredient or product manufacturers.
Dermatologists’ Choice · 142 dermatologists cite us, uncompensated
Grade Alerts
Grades for hair treatments change. Know when they do. Get an alert when a grade moves, plus each new review. About 2 emails a month. No products, no sponsors.
© 2026 The Trichology Review · Editorial independence policy